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Abstract
Aims Chronic heart failure (CHF) can be caused by autoantibodies stimulating the heart via binding to first and/or second
extracellular loops of cardiac β1-adrenoceptors. Allosteric receptor activation depends on conformational features of the au-
toantibody binding site. Elucidating these features will pave the way for the development of specific diagnostics and therapeu-
tics. Our aim was (i) to fine-map the conformational epitope within the second extracellular loop of the human β1-
adrenoceptor (β1ECII) that is targeted by stimulating β1-receptor (auto)antibodies and (ii) to generate competitive cyclopeptide
inhibitors of allosteric receptor activation, which faithfully conserve the conformational auto-epitope.
Methods and results Non-conserved amino acids within the β1ECII loop (compared with the amino acids constituting the ECII
loop of the β2-adrenoceptor) were one by one replaced with alanine; potential intra-loop disulfide bridges were probed by
cysteine–serine exchanges. Effects on antibody binding and allosteric receptor activation were assessed (i) by (auto)antibody
neutralization using cyclopeptides mimicking β1ECII ± the above replacements, and (ii) by (auto)antibody stimulation of human
β1-adrenoceptors bearing corresponding point mutations. With the use of stimulating β1-receptor (auto)antibodies raised in
mice, rats, or rabbits and isolated from exemplary dilated cardiomyopathy patients, our series of experiments unmasked
two features of the β1ECII loop essential for (auto)antibody binding and allosteric receptor activation: (i) the NDPK
211–214 motif
and (ii) the intra-loop disulfide bond C209↔C215. Of note, aberrant intra-loop disulfide bond C209↔C216 almost fully disrupted
the functional auto-epitope in cyclopeptides.
Conclusions The conformational auto-epitope targeted by cardio-pathogenic β1-receptor autoantibodies is faithfully con-
served in cyclopeptide homologues of the β1ECII loop bearing the NDPK
211–214 motif and the C209↔C215 bridge while lacking
cysteine C216. Such molecules provide promising tools for novel diagnostic and therapeutic approaches in β1-autoantibody-
positive CHF.
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Introduction
Dilated cardiomyopathy (DCM)—defined as progressive car-
diac dilatation and dysfunction without coronary heart dis-
ease—mostly affects younger adults. It frequently entails
severe heart failure and transplantation. Prevalence and an-
nual incidence amount to 0.5% and 0.1%, respectively.1 Ac-
cording to the 2008 ESC cardiomyopathy classification—
within the non-familial forms—autoimmune DCM has been
recognized as a proper pathogenetic entity.2 Autoimmunity
arising from acute myocardial inflammation induced by micro-
bial or viral agents is considered one key factor in the patho-
genesis of autoimmune DCM. Progress to chronic
immune-cardiomyopathy and chronic heart failure (CHF) is
common in patients unable to clear the infecting agent,3
showing persistent inflammation,4 and/or having a familial
pre-disposition to autoimmune reactions.5 DCM autoimmu-
nity encompasses autoantibodies directed against myocardial
antigens6–8 and cardiovascular G-protein-coupled receptors
(for review, see Boivin-Jahns and Jahns9), most notably the
β1-AR.
10–13 The latter (termed anti-β1-aabs) are suspected to
play a pivotal pathogenic role because anti-β1-aab-positive
compared with aab-negative DCM patients have a more se-
verely depressed cardiac function13 and a threefold increased
risk for cardiovascular death.10 The incidence of anti-β1-aabs
can precede DCM symptoms by many years,14 and selective
removal of anti-β1-aabs can decelerate disease progression
and improve outcome in β1-aab-positive DCM patients.
15,16
Most DCM-relevant anti-β1-aabs trigger a similar conforma-
tional switch of the β1-AR molecule as the true agonists
17
and elicit detrimental cardiac effects similar to chronic cate-
cholamine challenge. The pathogenic relevance of stimulating
anti-β1-aabs in DCM is corroborated by DCM equivalents in-
duced in rodents by β1-AR immunization, isogenic antibody
transfer, and corresponding rescue experiments.11,18–20 At
bottom line, chronic cAMP stimulation by anti-β1-aabs appears
to play amajor role in DCM pathogenesis. Because blockade of
sympathetic hormone receptors by beta-receptor antagonists
has proven beneficial in CHF, a first logical step was to explore
whether these drugs could also (pharmacologically) neutralize
the cellular effects of stimulating anti-β1-aabs.
21 Although β1-
selective (e.g. bisoprolol and metoprolol) and non-selective
beta-blockers (e.g. alprenolol and carvedilol) were able to sig-
nificantly reduce anti-β1-aab-stimulated cAMP production, in
the end, all tested substances—even at saturating concentra-
tions—blocked anti-β1-aab-mediated effects only partially
[resulting in a 50% (alprenolol) up to 70% (carvedilol) reduc-
tion of the antibody-induced fluorescence resonance energy
transfer (FRET) signals]. Consequently, clinical disease man-
agement would greatly profit from diagnostic determination
and direct targeted intervention against stimulating anti-β1-
aabs, but the prerequisite knowledge of the structural fea-
tures of the auto-epitope crucial for cAMP stimulation is yet
too limited for that.
DCM-relevant anti-β1-aabs target the first (β1-ECI) and/or
second extracellular loops (β1-ECII) of the β1-AR.
22,23 IgG
binding to immobilized linear peptides representing
these domains has been used to determine the
prevalence of anti-β1-aabs in various diseases. However,
these assays exhibit low sensitivity/specificity and, in gen-
eral, fail to discriminate patients from healthy subjects in
a non-random fashion, because the disease-relevant anti-
β1-aabs target specific conformations of β1-ECI and/or β1-
ECII that are not properly represented by immobile linear
peptides. To date, DCM-relevant anti-β1-aabs can only be
detected by native assays or functional readouts.19,24,25
However, the many patients potentially to be screened for
anti-β1-aabs (i) require clinical diagnostics based on conven-
tional procedures [e.g. enzyme-linked immunosorbent assay
(ELISA)] for measuring IgG binding to synthetic representa-
tions of the very auto-epitope conformation specifically
targeted in the course of allosteric β1-AR activation.
17,24 In-
terestingly, circular peptide representations of β1-ECII (alone
or as an add-on to cardioselective β1-blockers) could stop
progression and even revert CHF in rats subjected to β1ECII
immunization(s), whereas cardioselective β1-blockers alone
were only able to stabilize the dilated cardiomyopathic
phenotype.19,20 Therefore, cyclopeptides might provide an
adequate synthetic mimic of the DCM-relevant conforma-
tional auto-epitope. Following up on this idea, we unmask
here the structural features within β1-ECII that are essential
and specific for allosteric receptor activation by anti-β1-aabs
and required in cyclopeptides for a neutralization of that
effect.
Methods
Anti-β1ECII antibodies
Anti-β1ECII antibodies were raised in male Lewis rats
11 or
rabbits (Dianova, Hamburg, Germany) or mice (mouse
Mab 23-6-7, BioGenes, Berlin, Germany26) by immunization
with β1-ECII/glutathione S-transferase (GST) fusion proteins.
In addition, a monoclonal rat antibody was generated by
fusing spleen cells from anti-β1ECII-positive immunized rats
with a multiple myeloma Sp2/0-Ag14 cell-line (rat Mab
13F626). Hybridoma cells expressing mouse Mab 23-6-7
and rat Mab 13F6 were submitted to DSMZ-Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH
(Braunschweig). Depositing was carried out according to
the rules of the Budapest Treaty (accession numbers DSM
ACC3121 and ACC3174).
Human anti-β1-aabs were gained from representative
CHF patients.21 Because of the relatively large amounts of
serum necessary to isolate human IgG for the serial func-
tional assays, as a proof of concept in the present work,
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IgG was isolated from three DCM patients only {two men
[56a, New York Heart Association (NYHA) IV, left ventricular
ejection fraction (LVEF) 29%, and 53a, NYHA III, LVEF 31%]
and one woman (29a, NYHA IV, LVEF 26%)}. In all three pa-
tients, LVEF was determined by ventriculography, and coro-
nary heart disease was excluded by coronary angiography.
At the time of invasive diagnostics, all three patients were
stable under standard CHF medication including
angiotensin-converting enzyme inhibitor/AT1 receptor
blockers, beta-blockers, and aldosterone antagonists. In
none of the patients, exposure to cardio-toxic substances,
myocarditis, or other systemic heart diseases was evident
from clinical history. IgG was freshly isolated from the re-
spective (human or animal) sera and dialyzed against the
appropriate assay buffers. Immuno-reactivity of rodent IgG
against a linear 25 amino acid (AA) β1ECII peptide (residues
199–123) was determined by ELISA.12,13
Cyclopeptides
Cyclopeptides corresponding to AA residues 200–220 of the
human β1-AR and constituting the entire β1-ECII
27 were
cyclized between the C-terminal glutamate and the free
N-terminal amino group (Peptide Speciality Laboratories,
Heidelberg, Germany). Non-conserved residues differing be-
tween the β1-AR and β2-AR were sequentially substituted
by alanine. Cysteine216 (C216) was replaced with α-
aminobutyric acid (B) to prevent aberrant disulfide bridging
to C209. Corresponding 22-mer cyclopeptides of the second
extracellular loop of the human β2-adrenergic receptor (β2-
ECII) served as negative controls. In 18-mer cyclopeptides
representing a minimal ECII structure encompassing resi-
dues 204–219 of the human β1-AR, C
215 or C216 was re-
placed with serine to selectively disrupt potential
intra-loop disulfide bridges (for further details, see Figure
2 and Table S1). Cyclopeptides were freeze-dried,
reconstituted in water, and stored at 20°C. For the func-
tional assays, anti-β1-abs/β1-aabs were pre-incubated with
40 mol of cyclopeptides/mol IgG, assuming a 1:1 stoichiom-
etry between the cyclic 22AA-ECII peptide variants
(~3.0 kDa) and one IgG molecule (~150 kDa). In fact, the
molar excess was only 20-fold, assuming two variable
(Fab) chains with two antigen-binding regions per IgG mol-
ecule. Antigen-binding regions are further subdivided into
hypervariable (HV) and framework (FR) regions; HV regions
comprise about five to eight AAs directly contacting a por-
tion of the antigen’s surface.28 IgG was freshly isolated
from the respective (human or animal) sera by caprylic acid
precipitation, dialyzed against the appropriate assay buffers,
and allowed to interact with the Cyclopeptides (CPs) for
16 h at 4°C (cold room) in an Eppendorf cup on a gently
rotating incubator. After short spin, the supernatant was
used for the assays.
cAMP measurements by a fluorescence
resonance energy transfer sensor
cAMP measurements by a FRET sensor using HEK-β1E1 cells
stably co-expressing the human β1-AR and a FRET sensor for
intracellular cAMP followed published procedures.21 Cells
were grown on poly-D-lysin-coated 96-well plates (Ibidi,
Martinsried, Germany). Endogenous β2-AR was blocked with
ICI-118551 (0.1 μM). Cells were imaged with a fluorescence
microscope optimized for the cyan fluorescent protein
(CFP)/yellow fluorescent protein (YFP) donor/acceptor pair
of the cAMP sensor (iMIC 2000, TILLPhotonics, Martinsried,
Germany); CFP/YFP emissions were continuously recorded
for 32 min. FRET efficiency reflecting intracellular cAMP levels
was calculated every 6 s using TillvisION v4.5.59
(TILLPhotonics) and OriginPro 8G (OriginLab, Northampton,
USA). Antibody effects normalized to agonist maximum were
derived from successive determinations of baseline (10 min)
and effect of the antibody tested (20 min) and of ()-isopro-
terenol (1 μM, 2 min) performed on sets of ≈500 cells.
β1-AR mutants
cDNA constructs of the human β1-AR bearing point mutations
E202A, R207A, D212N, P213A, or V219A were generated by
site-directed mutagenesis (Table S2), confirmed by sequenc-
ing, transiently expressed in HEK293 cells, and characterized
by Western blotting and radioligand displacement.21 To en-
sure reproducibility (and sufficient supply) of the test agent
‘anti-β1ECII antibody’ for our experiments with human β1-AR
mutants, we used monoclonal anti-β1ECII-abs raised in mice
(Mab 23-6-726) or rats (Mab 13F626), thereby reducing the
variability due to potentially different HV regions of poly-
clonal rabbit, rat, or human IgGs used in the experiments
before.28 HEK293 cells expressing human β1-AR with the indi-
cated point mutations were exposed (60 min, 37°C) to anti-β-
1ECII-Mabs (0.2 μg/μl) or ()-isoproterenol (1 μM) in the
presence of 3-isobutyl-1-methylxanthine (100 μM) and
ICI-118551 (37.5 pM). Cellular cAMP was measured by RIA
(Coulter-Immunotech, Krefeld, Germany).
Statistics
After testing for normal distribution (comparable variances
on the means of each group), data were analysed by
one-way analysis of variance (ANOVA) with subsequent
Dunnett’s post-hoc test for multiple comparisons (comparing
all means against the control/reference mean) using
GraphPad PRISM 8 (version 8.3.1, GraphPad Software Inc.,
USA).
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Ethics
Animal experiments were approved by the animal ethics
committee of the Government of Lower Franconia (Vote
No. 55.2-2531.01-52/08, Experimental Animal Use and Care
Committee, Government of Lower Franconia, Bavaria,
Germany). The study of patient’s biomaterials complies with
the Declaration of Helsinki and was approved by the Medical
Ethics Committee of the Medical Faculty of the University of
Würzburg (Vote No. 186/07). Informed consent of the donors
was obtained.
Results
Role of intra-loop disulfide bridges in
auto-epitope conformation
The β1-ECII contains three cysteines significantly determining
loop conformation: C209 and C215 form an intra-loop disulfide
bridge, while C216 forms a bridge to β1-ECI.
29 In cyclopeptides,
a possible aberrant bridge C209↔C216 can alter the physio-
logical conformation. To address whether this plays a role
for binding and allosteric receptor activation by anti-β1ECII-
abs, we synthesized two minimal (18-mer) cyclopeptides
representing AA residues 204–219 of the β1-ECII, which had
either C215 (termed 18 C/C/S) or C216 (termed 18 C/S/C) re-
placed by serine, thereby allowing either the physiological
bridge C209↔C215 or the aberrant bridge C209↔C216 (Table
S1). The reactivity of these cyclopeptides with stimulating
anti-β1ECII-abs was assessed using sera of 99 rats having de-
veloped high titres of anti-β1ECII-abs and a cardiac DCM phe-
notype after repeated immunizations with β1ECII/GST fusion
proteins.19,20 First, we investigated pre-adsorption of these
rat anti-β1ECII-abs to either 18-mer cyclopeptide (at 40-fold
molar excess) prior to ELISA with linear 25-mer β1ECII pep-
tides. Binding of the large majority of sera (83/99 = 84%)
was neutralized by 18 C/C/S (bearing the physiological bond
C209↔C215), but not by 18 C/S/C (bearing the aberrant bond
C209↔C216). Only four sera were neutralized by 18 C/S/C,
and 12 rat sera could not be fully blocked with either
cyclopeptide (Table 1).
Because β1-AR-mediated cAMP stimulation is the readout
delineating the clinically relevant cardio-pathogenic potential
of anti-β1ECII-abs,
10 we next analysed neutralization of the
cAMP stimulatory effect of rabbit anti-β1ECII-abs using HEK-
β1E1 cells co-expressing human β1-AR with a cAMP FRET
reporter.21 In these cells, intracellular cAMP levels can be
continuously monitored via the CFP/YFP emission ratio of
the FRET sensor, and cAMP stimulation by anti-β1ECII-abs
can be normalized to the maximal stimulation obtained with
1 μM ()-isoproterenol, measured in the same batch of cells.
Rabbit anti-β1ECII-abs increased cAMP levels by about
18.8 ± 1.2% of the maximum achieved with the full agonist
()-isoproterenol. Pre-absorption of rabbit anti-β1ECII-abs to
18 C/C/S (the 18-mer cyclopeptide with the physiological
bond C209↔C215; 40-fold molar excess) reduced the stimula-
tory effect of the antibodies by more than 50% (9.4 ± 2.2%;
P < 0.01). By contrast, pre-absorption of rabbit anti-β1ECII-
abs to 18 C/S/C (the cyclopeptide with the aberrant bond
C209↔C216; 40-fold molar excess) failed to block the
antibody-induced increases in intracellular cAMP
(18.1 ± 2.0%, n.s.; Figure 1). In conclusion, inhibition of anti-
β1ECII-induced β1-AR activation by β1ECII-mimicking
cyclopeptides requires the natural intra-loop disulfide bridge
C209↔C215 and is disrupted by the non-physiological
C209↔C216 bond.
β1ECII loop residues essential for proper
conformation of the auto-epitope
Even the 18-mer cyclopeptide with the appropriate disulfide
bridge yielded only incomplete inhibition, indicating that an
optimal representation of the auto-epitope conformation
might require longer constructs with a less bulky C216 substi-
tution. Accordingly, a 22-mer cyclopeptide was generated,
representing the entire predicted β1ECII loop and having cys-
teine C216 replaced by α-aminobutyric acid (B), an artificial
cysteine homologue not engaging in disulfide bridges. This
optimized construct (22 C/C/B-β1, depicted in Figure 2)
inhibited anti-β1ECII antibody-induced stimulation by ≥80%
(Figure 3, first black column on the left) and served as a tem-
plate to map further residues within β1ECII essential for the
proper conformation of the auto-epitope. Nine variants of
22 C/C/B-β1 were synthesized, each having a different
non-conserved AA (compared with the AA constituting the
ECII loop of the β2-AR) sequentially replaced by alanine
(E202A, S203A, D204A, R207A, R208A, N211A, D212A,
P213A, and K214A). Conserved AA residues essential for
Table 1 Effect of intra-loop disulfide bonds on the binding of anti-β1-ECII-abs
a
Neutralizing cyclopeptides (40 mol/mol IgG)
Effective pre-adsorption of anti-β1ECII rat sera (n) (≥90%
reduction in ELISA reactivity with β1-ECII peptides)
18-mer C/C/S (C209↔C215) 83 (84%)
18-mer C/S/C (C209↔C216) 4 (4%)
Not fully blocked 12 (12%)
aDetermined by enzyme-linked immunosorbent assay (ELISA) of IgG binding to a linear 25 AA β1-ECII peptide.
12,13
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adrenoceptor function per se were omitted from the scan (for
details, see Table S1).
The reactivity of the 22-mer C/C/B-β1 variants with clini-
cally relevant stimulating anti-β1ECII-abs was determined by
(i) pre-absorption of autoantibody binding to the linear 25
AA β1ECII peptide (determined by ELISA) and by (ii)
pre-absorption of the receptor-stimulating capacities of
anti-β1ECII-abs (determined with cAMP FRET reporter cells).
Sera of β1ECII/GST-immunized cardiomyopathic rats served
as a source for DCM-relevant autoantibodies. Mean results
obtained with sera from 20 individual rats are summarized
in Figure 3, demonstrating that receptor binding (grey col-
umns) and receptor stimulation (black columns) were effi-
ciently pre-absorbed (>80%) by all cyclopeptide mutants
tested, except for those having disrupted an NDPK motif
encompassing AA residues 211–214. The most disruptive mu-
tation was P213A, which almost completely abolished the
scavenger effect of the respective cyclopeptide (blocking ca-
pacity 22 C/C/B-β1 vs. P213A: 87.9 ± 3 vs. 7.2 ± 8%,
P < 0.0001). The same was observed with a stimulating
monoclonal mouse anti-β1ECII antibody (Figure S1).
To confirm the clinical relevance of these results, compara-
ble neutralization experiments were performed with
stimulating anti-β1-aabs isolated from selected DCM patients.
Figure 4A shows a representative recording of cAMP reporter
signals obtained with patient-derived anti-β1-aabs, which in-
duced an increase in β1-AR-mediated cAMP production of
≈30% of the maximal signal obtained with saturating concen-
trations (1 μM) of the full agonist ()-isoproterenol. That
stimulatory effect was almost fully abolished by
pre-incubation with the (non-mutated) cyclopeptide 22 C/C/
B-β1, whereas the mutant P213A (earlier found ineffective af-
ter pre-absorption of rodent anti-β1ECII-abs; Figure 3 and Fig-
ure S1) also failed to block the stimulatory effect of human
anti-β1-aabs (Figure 4A). The blocking profile of the entire
set of mutated cyclopeptides on cAMP stimulation by human
anti-β1-aabs isolated from selected antibody-positive DCM
patients (male/female) is shown in Figure 4B.
In summary, our data suggest that the NDPK211–214 motif
within β1-ECII is of paramount relevance for β1-AR-induced
cAMP stimulation by potentially cardio-pathogenic anti-β1-
aabs. The stimulatory effect of human DCM-associated auto-
antibodies appeared even more sensitive to disruptions of
the NDPK211–214 motif than the effect of anti-β1ECII-abs raised
in rodents. Moreover, cAMP stimulation by human anti-β1-
aabs was also affected by the adjacent mutation R208A (Fig-
ure 4B vs. Figure 3, black columns), suggesting that the
auto-epitope targeted by human anti-β1-aabs is slightly
larger, encompassing the motif R (CY)NDPK208–214. This find-
ing is not unexpected because our rodents through repeated
immunizations have undergone a maturation process in their
adapted immune system, entailing increases in antibody avid-
ity and epitope narrowing,30 which human DCM patients
most probably have not undergone (explaining the generally
lower levels and lower avidity of human anti-β1-aabs
25).
The black labels in Figure 2 summarize the results obtained
in our experiments aiming at a further refinement of
cyclopeptides intended as synthetic targets or therapeutic
scavengers of stimulating anti-β1-aabs. Minimal requirements
for such agents encompass a core domain of eight essential
AA ranging from positions 208 to 215 of the human β1-AR se-
quence, which harbours the essential intra-loop bridge
C209↔C215. Aberrant disulfide bridging to C216 must be pre-
cluded. The core domain should be embedded in a protein
circle encompassing the entire β1ECII loop to be fully efficient.
Directed mutational analysis of the
presumed auto-epitope in intact
human β1-ARs
Our above results regarding the auto-epitope of stimulatory
anti-β1ECII-abs led to the assumption that the generated neu-
tralizing (scavenger) cyclopeptides represent competitive in-
hibitors faithfully mimicking the three-dimensional structure
of the auto-epitope as presented on native β1-ARs. To
Figure 1 Neutralization of the stimulatory effects of rabbit anti-β1ECII-abs
by pre-incubation with cyclopeptides containing intra-loop bonds
C209↔C215 (18 C/C/S) or C209↔C216 (18 C/S/C): Stimulatory effects of
polyclonal rabbit anti-β1ECII-abs on the human β1-AR coupled to a CFP/
YFP-FRET sensor for intracellular cAMP, normalized to maximal stimula-
tory effects obtained by 1 μM ()-isoproterenol. Rabbit anti-β1ECII-abs
were pre-absorbed with the indicated cyclopeptides (40 mol CP/mol
IgG). Unblocked: effect of stimulating rabbit anti-β1ECII-abs alone. Data
are given as mean ± SEM (n ≥ 5 per experiment; differences between
the conditions were analysed by one-way ANOVA with subsequent
Dunnett’s post-hoc test for multiple comparisons; **P < 0.01).
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confirm this assumption, we then investigated whether the
very same AA residues essential for antibody neutralization
by cyclopeptides would also be relevant for the interaction
of stimulating anti-β1ECII-abs with full-length human β1-ARs.
For this purpose, we generated β1-AR constructs bearing
point mutations of AA residues either presumed to be essen-
tial components of the core auto-epitope (D212N and P213A)
or flanking the core auto-epitope while not essentially con-
tributing to its formation (R207A and V219A). The mutant
β1-ARs were expressed in HEK293 cells. Expression and func-
tionality of the β1-AR mutants were ascertained (i) by ligand
binding and (ii) by cAMP responses compared with the
wild-type β1-AR expressed under same conditions (Table S3).
To ensure reproducibility of the test agent anti-β1ECII anti-
body, we then measured the cAMP responses induced via the
mutant β1-ARs by two different monoclonal anti-β1ECII-abs
(Mab 23-6-7 or Mab 13F6, raised in mice or rats,
respectively26). Whereas the cardio-noxious potential of
anti-β1ECII-Mabs generated in mice (as Mab 23-6-7) has been
clearly shown independently by many research groups,30–32
the clinical relevance of rat anti-β1ECII-Mabs remained to be
demonstrated. Thus, according to our previously described
strategy11—after purification from the cell supernatant—we
(intravenously) transferred Mab 13F6 into healthy rats every
4 weeks. Compared with animals receiving a rat IgG isotype
control, rats receiving Mab 13F6 within (6 to) 9 months of
Mab transfer developed a dilated cardiomyopathic pheno-
type (Figure S2), demonstrating its disease-inducing
potential.
To rule out effects of the mutations on β1-AR function per
se, increases in cAMP were again normalized to the maximal
stimulation achieved for each β1-AR mutant by the full ago-
nist ()-isoproterenol (1 μM). As summarized in Figure 5,
β1-ARs bearing mutations within the presumed auto-epitope
(D212N and P213A) were significantly (P < 0.0001) less sen-
sitive to stimulation by rat or mouse anti-β1ECII-Mabs than
the wild-type β1-AR. In contrast, cAMP stimulation by rat or
mouse anti-β1ECII-Mabs was not significantly (P ≥ 0.01) af-
fected by mutations in the flanking regions (R207A and
V219A), previously found to be not involved in the scavenger
Figure 2 Schematic representation of the 22-mer C/C/B-β1 cyclopeptide mimicking the human β1ECII bearing the essential motif of the clinically rele-
vant auto-epitope: circles with capitals specify amino acids (single letter code). Numbers specify their position in the sequence of the human β1-AR. ‘B’
stands for the artificial amino acid α-aminobutyrate substituting C216 in order to prevent a non-physiological S-S-bond C209↔C216. Boxed letters N and
C indicate the termini of the predicted β1ECII loop. The full line between C
209
and C
215
indicates the essential intra-loop disulfide bridge; black circles
depict amino acid residues essential for the neutralization of stimulating rodent anti-β1ECII-abs. Grey circles represent additional amino acid residues
supposed to be relevant for the neutralization of stimulating human anti-β1ECII-aabs. Amino acid residues R
207
, E
205
, S
203
, and T
220
were not found
essential by directed mutational analysis.
6 A. Wölfel et al.
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.12747
effect of cyclopeptides (Figures 2 and 3B). In conclusion, the
same AA residues essential for antibody neutralization by
cyclopeptides (Figures 3 and 4) appear also essential for the
anti-β1ECII-induced activation of native human β1-AR (Figure
5). Consequently, cyclopeptides that faithfully mimic the
auto-epitope conformation relevant for allosteric β1-AR acti-
vation should also efficiently block the effects of stimulating
anti-β1ECII-abs.
Figure 4 Neutralization of human anti-β1-aabs from DCM patients by 22-mer cyclopeptides mimicking β1ECII with non-conserved amino acids (com-
pared with the amino acids constituting the ECII loop of the β2-AR) sequentially replaced by alanine: human anti-β1-aabs (IgG fractions) were
pre-absorbed with the indicated cyclopeptide mutants (40 mol/mol IgG, 4°C, 16 h). Anti-β1-aab-induced cAMP production was measured in HEK293
cells expressing the native β1-AR functionally coupled to a cAMP FRET sensor. (A) Representative recordings of FRET ratios obtained upon addition
of anti-β1-aabs prepared from a male DCM patient followed by the maximal signal achieved with 1.0 μM of ()-isoproterenol (Iso). (B) Prevention
of cAMP stimulation after pre-absorption of patient anti-β1-aabs. Results are normalized to the values without pre-absorption. Columns represent
mean ± SEM from at least three to four independent experiments with IgG prepared from different exemplary DCM patients (two men and one
woman). Differences between the non-mutated 22 C/C/B-β1 cyclopeptide and CP mutations were analysed by one-way ANOVA with subsequent
Dunnett’s post-hoc test for multiple comparisons; *P< 0.05; **P < 0.01; ***P< 0.001. Internal negative control: non-mutated 22C/C/D-β2 (sequence
and alignment, see Table S1).
Figure 3 Neutralization of the functional effects of polyclonal rat anti-β1ECII-IgG by 22-mer cyclopeptides mimicking the human β1-ECII with
non-conserved amino acids (compared with the amino acids constituting the ECII loop of the β2-AR) sequentially replaced by alanine: sera of 20
cardiomyopathic Lewis rats (immunized with β1ECII/GST fusion proteins) were pre-absorbed with the indicated cyclopeptide mutants (40 mol CP/
mol IgG, 4°C, 16 h). Grey bars: IgG binding to the linear 25 AA (199–223) β1ECII peptide as determined by ELISA (triplicates). Black bars: β1-AR-mediated
cAMP stimulation in HEK293 cells expressing native β1-AR functionally coupled to a cAMP FRET sensor. Decreases in ELISA reactivity (grey bars) or re-
ceptor activation/cAMP stimulation (black bars) following pre-absorption with the different cyclopeptide mutants are shown, normalized to the values
obtained without blocking cyclopeptides. Columns represent mean values ± SEM of n = 20 rat sera. Differences between the non-mutated 22 C/C/B-β1
cyclopeptide and CP mutations were analysed by one-way ANOVA with subsequent Dunnett’s post-hoc test for multiple comparisons; *P < 0.05;
**P < 0.01; ***P < 0.001; †P < 0.0001. Internal negative control: non-mutated 22C/C/D-β2 (sequence and alignment, see Table S1).
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Discussion
We here provide a set of direct and indirect evidence delin-
eating the minimal structure and conformation of the β1-AR
epitope targeted by anti-β1-aabs supposed to play an impor-
tant role in various cardiovascular disorders.9 Allosteric β1-AR
activation by these autoantibodies is considered a severe risk
factor if not a cause of CHF.10,11 It is long known that such
stimulating aabs mostly target the β1-ECII.
23 However, at-
tempts at further narrowing the target epitope have yielded
ambiguous results: autoantibodies involved in Chagas cardio-
myopathy are thought to target residues 201–20533; in
post-partum cardiomyopathy, the autoantibody target has
been placed at residues 200–210; and for DCM, a whole se-
ries of overlapping sequences have been published (residues
183–208, 197–202, 206–212, and 213–21822,23,33),
encompassing almost the entire β1-ECII and even portions of
the adjacent transmembrane domain VI. Almost all these
data have been obtained with linear peptides as probes.
However, the surface of a protein is essentially a continuum
of potential epitopes, but the fact that functional epitopes
are often found to be discontinuous shows that mapping by
linear peptide scanning may not be generally useful for com-
prehensive mapping or analysis of functional (energetic)
epitopes.34 By now, it seems quite clear that
disease-relevant anti-β1-aabs are only those that stimulate
the β1-AR
21 and that such aabs bind to a conformational epi-
tope, thereby stabilizing an active conformation and
prolonging the active state of the β1-AR.
17 Consequently,
stimulating anti-β1-aabs poorly cross-react with linear
peptides,12,13,24 which probably explains why epitope map-
ping with linear peptides has not yielded a clearer picture
of the relevant β1-AR auto-epitope(s). However, such a
clearer picture is desperately needed for the development
of specific diagnostics and therapeutics addressing this dis-
ease mechanism.
One crucial and potentially clinically relevant finding of
our study is the identification of a minimal peptide struc-
ture that efficiently hinders receptor stimulation by
DCM-associated human anti-β1-aabs in an experimental ap-
proach using cells expressing functionally coupled human
β1-ARs. We have previously demonstrated that
cyclopeptides mimicking that structure can stop progression
of CHF and even partially revert the CHF phenotype in a
human-analogous rat model of autoimmune DCM.19,20 This
therapeutic effect is conveyed not only by scavenging (and
thus neutralizing) cardio-pathogenic anti-β1ECII-abs but pos-
sibly also by induction of B-cell tolerance.35 In support of
this hypothesis, we observed in the above therapy model
not only a reduction of autoantibody titres due to in vivo
scavenging of circulating anti-β1ECII-abs but also a reduction
of anti-β1ECII-secreting B cells.
19 While long-lived plasma
cells express very little or no immunoglobulins on the cell
surface,36 B cells do and could thus also serve as targets
of β1ECII-CPs. To detect the few antigen-specific memory
B cells within splenocytes of CP-treated vs. untreated im-
munized rats, in our previous study, we differentiated
memory B cells into short-lived plasma blasts by boosting
Figure 5 Stimulation of mutant β1-ARs bearing point mutations within or flanking the presumed auto-epitope of functional anti-β1ECII antibodies: to
ensure reproducibility of the test agent anti-β1ECII antibody, HEK293 cells expressing human β1-AR with the indicated point mutations were exposed
to monoclonal anti-β1ECII-abs raised in mice (mouse Mab 23-6-7,
26 white columns) or rats (rat Mab 13F6,26 grey columns). cAMP levels were deter-
mined in the cell lysates by radio-immunoassay. For each experiment, increases in cAMP following antibody exposure were normalized to the maximal
responses achieved with 1.0 μM of the full agonist ()-isoproterenol. Data are given as mean ± SEM of at least six independent experiments per col-
umn. Differences between the wild-type β1-AR and the indicated mutants were analysed by one-way ANOVA with subsequent Dunnett’s post-hoc test
for multiple comparisons; **P < 0.01; †P < 0.0001.
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the rats with β1ECII/GST-FPs 3 days prior to the analysis of the
spleens. Whereas long-lived plasma cells were not targeted by
β1ECII-CPs, preventive as well as therapeutic application of the
same CPs resulted in a ~ 80% reduction of the frequencies of
splenocytes secreting anti-β1ECII-abs.
19 This finding indicates
that in immunized anti-β1ECII-positive rats, repeated injec-
tions of β1ECII-CPs may lead to impaired B-cell receptor
(BCR)-mediated β1ECII-specific memory B-cell expansion (and
differentiation into anti-β1ECII-producing plasma cells). Thus,
cyclopeptides based on the criteria outlined in the present
study may complement therapeutic strategies that exclusively
aim at (non-specific) autoantibody scavenging, such as extra-
corporeal IgG absorption37 or the systemic application of
aptamers.38
Furthermore, the very same peptide core conveying to
cyclopeptides the potency to prevent allosteric β1-AR activa-
tion by anti-β1ECII-aabs is obviously also a crucial prerequisite
of the allosteric stimulation mechanism itself, which implies
that the cyclopeptide actually mimics the 3D structure of
the auto-epitope that provides the allosteric trigger. The pro-
posed antibody-binding region as outlined in Figure 2 com-
prises the essential motif NDPK211–214 framed by the equally
essential disulfide bridge between cysteines C209↔C215. In
the intact receptor, this structure is constrained by another
adjacent disulfide bridge linking C216 to the transmembrane
region next to ECI. Both pairs of disulfide bridges are relevant
for receptor function.39,40 According to the 3D structure of
the turkey β1-AR,
41 the assumed auto-epitope is located at
the C-terminal end of the backward-oriented α-helix consti-
tuting β1-ECII. Several features pre-dispose the NDPK
211–214
motif as an autoantigen and allosteric trigger: N211, D212,
and K214 are prone to bond with the binding surface of the
antibody, while P213 is needed to interfere with the
H-bond formation to neighbouring helix residues, thereby
bending the local α-helix42 and creating a unique structure
for antibody recognition. The allosteric activation trigger is
most probably provided by D212, the exchange of which
to asparagine is known to cause paradoxical receptor acti-
vation by antagonistic ligands.43
Limitations
The fact that human anti-β1-aabs are polyclonal and that the
concentration of specific anti-β1-aabs in the circulation of a
patient is probably much lower than in specifically immunized
anti-β1ECII-positive rodents represents a major challenge for a
therapeutic use of the here described cyclopeptides in the fu-
ture. Immunoglobulin G after maturation by its (antigen-bind-
ing) HV regions assumingly recognize stretches of five (to
eight) AAs as a target epitope.28,34 The ECII loop of the β1-
AR is thought to be composed of 30 AAs (AA 195–225 of
the receptor protein), and most functionally active human
anti-β1-aabs were shown to be directed against this segment
of the β1-AR membrane protein, representing a readily acces-
sible target on the cell surface. Thus, it seems conceivable
that polyclonal human anti-β1-aabs may target different epi-
topes (stretches of five to eight AAs) even within the 30
AAs that constitute β1ECII, which might result in diverging
functional effects and/or downstream effects.12 Moreover,
not only the specific target epitope (at the surface of a same
target protein) but also the target protein itself (which might
be sarcolemmal proteins, such as myosin or troponin, or
myocyte membrane proteins such as β1-AR, β2-AR, β3-AR,
M2-muscarinergic, and/or angiotensin II AT1 receptors), or
cross-reactions (or molecular mimicry44) between the target
protein and other functionally relevant proteins may contrib-
ute to the diversity of functional effects and/or downstream
effects of human aabs. In case of cross-activation of β1-AR
by human anti-myosin aabs,45 β1-derived cyclopeptides
would probably fail to hinder anti-myosin-aab-induced stimu-
lation of cardiac β1-AR. Assessment of the effect of human
aabs on downstream signalling might be even further compli-
cated by the co-existence of aabs against different target pro-
teins, which could then enhance (additive effect) or inhibit
(opposing effect) downstream signalling and would require
a panel of different epitope-mimicking CPs to be therapeuti-
cally used on a case-to-case basis (e.g. human anti-β1-aabs
were shown to increase cAMP production, whereas human
anti-M2-aabs inhibit cAMP production,46 or myocardial dam-
age induced by anti-β1-aabs in heart failure was found to be
alleviated by human anti-β2-aabs
47).
Next steps and clinical perspective
As a consequence (and because of the pilot character of
our study, testing only a few exemplary DCM patients), it
will be necessary to fine-map the target epitopes of anti-β-
1ECII-aabs of a larger number of CHF patients (with differ-
ent aetiologies, e.g. DCM vs. ICM vs. hypertensive heart
disease) to confirm our findings. Because human anti-β1-
aabs are polyclonal, their target epitope(s) might encom-
pass not only the here unmasked structural motif in β1-ECII,
but also structural motifs in other extracellular domains of
the human β1-AR, for example, in β1-ECI,
10,22 which were
not addressed in the present study. Moreover, in future
(prospective) CHF studies, the patients should be systemat-
ically screened also for the presence of autoantibodies
against other cardiac membrane proteins. The functional ef-
fects and the specific target epitopes of each of these aabs
should then be analysed more in detail (e.g. for functional
tests by adapting the here described FRET approach and
for epitope fine-mapping by adapting the here described
Ala-scan approach). In the end, this could lead to the iden-
tification of functionally relevant (targetable) key epitopes
also in other G-protein-coupled membrane receptors.
Fine-mapping of functionally relevant key epitopes would
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allow to tailor epitope-specific cyclopeptides that (i) act as
autoantibody scavengers in the circulation and—in the light
of the data obtained by β1ECII-CP treatment of anti-β1ECII
antibody-positive rats19—might equally (ii) impair
BCR-mediated autoantibody-specific memory B-cell expan-
sion. Because the general risk of non-specific immune
(e.g. T-)cell activation increases with the size of a given (cy-
clo-)peptide from >25 AAs on,48 the exact knowledge of a
key epitope required to neutralize (or scavenge) functional
human aabs would allow to design much shorter (per se
less immunogenic) cyclopeptides, as we started in the pres-
ent study by testing 22-mer instead of 25-mer β1ECII-CPs
(used in our previous therapy study in anti-β1ECII
antibody-positive rats19). Even shorter CPs could be imag-
ined, comprising 18, 16, or even less AAs.
With the availability of a wide panel of
autoantibody-specific (preferably short) scavenger CPs, a fu-
ture therapeutic strategy could—in the end—comprise a kind
of personalized approach in autoantibody-associated CHF,
that is, the injection of an individualized mixture of tailored
cyclopeptides, depending on the autoantibody profile and
the downstream ‘net effect’ of cardio-noxious vs.
cardio-protective autoantibodies in an individual CHF patient.
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